Major Depressive Disorder (MDD) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

The major depressive disorder also referred to here as depression, is a serious medical illness that disrupts a person’s mood, behavior, thought processes, and physical health. Sadness and grief are normal reactions to life stresses. Other forms include bipolar disorder (manic-depressive illness) and dysthymia. In bipolar disorder, episodes of depression alternate with episodes of mania, a condition in which inappropriate or extreme “high” feelings may lead to dangerous, destructive behavior. Dysthymia involves symptoms similar to those of major depressive disorder. The decline in hippocampal function, which is believed to have an inhibitory effect on the hypothalamic-pituitary-adrenal (HPA) axis, could potentially be responsible for the hypercortisolemia seen in depression.

Pro-inflammatory marker levels are reported to be elevated in depressed patients, such as C-reactive protein (CRP), interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha (TNF-α).

According to research, the prevalence of MDD differs significantly across geographies, US (7.1%, 16.2 M) and Japan (4.7%, 5.0 M). In the US, MDD sufferers were more likely to be women than non-sufferers and were significantly younger (ps<0.05).

The competitive landscape of Major Depressive Disorder (MDD) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Major Depressive Disorder (MDD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Major Depressive Disorder (MDD)  Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Major Depressive Disorder (MDD)  – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          OPC-64005       Otsuka Pharmaceutical Co., Ltd.            Phase 2

2          Levomilnacipran            Forest Laboratories       Phase 3

3          LY03005           Luye Pharma Group Ltd.           Phase 3

4          PRAX-114         Praxis Precision Medicines        Phase 2

5          Cariprazine       Allergan            Phase 3

6          REL-1017         Relmada Therapeutics, Inc.       Phase 3

7          BTRX-335140   BlackThorn Therapeutics, Inc.    Phase 2

8          SPL026 Small Pharma Inc.         Phase 1/2

9          SAGE-217        Sage Therapeutics        Phase 3

10        AXS-05 Axsome Therapeutics    Phase 3

Continued